AfterMASH is regarded as one of the worst spinoffs ever produced, but its co-creator thinks one big change could have fixed its problems.
The results could have major implications for patients with metabolic dysfunction–associated steatohepatitis (MASH), particularly given that about 20% of patients with MASH progress to cirrhosis ...